Daniel Hertz, PHARMD, PHD
Interested in developing tools for individualizing cancer treatment, his current work focuses on the optimal use of taxane chemotherapy in patients with cancer. The approaches being developed include identifying an ideal systemic drug exposure target to maximize efficacy while avoiding unnecessary toxicity, particularly as it relates to chemotherapy-induced peripheral neuropathy. Hertz is also interested in understanding the influence of patient genetics on cancer treatment outcomes, with a particular interest in the clinical translation of DPYD testing to ensure safe fluoropyrimidine chemotherapy dosing. He uses several approaches to discover the effect of germline variants on treatment outcomes and translate these findings into clinical practice. Much of this work is conducted through collaboration with medical oncologists at the University of Michigan Rogel Cancer Center and within NCTN Groups including SWOG and Alliance.
Rogel Cancer Center
Breast cancer | Genetics / Genomics / other OMICS | Prostate cancer
- Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines
- Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer
- Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer